Organization | iCell Gene Therapeutics

iCell Gene Therapeutics Report issue

For profit Phase 1

Founded: New York NY United States (2014)

Organization Overview

First Clinical Trial

2018

NCT04156243

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

iCAR Bio | iCAR Bio, China | iCar Bio Therapeutics | iCAR Bio Therapeutics Ltd | iCAR Bio Therapeutics Ltd. | iCell Gene Therapeutics

Active Ingredients

Drugs in Phase 1 Trials (10)

bcma/cd19 dual-target car-t (2 trials)

bcma-cs1 ccar t cells (1 trial)

cd123-cd33 ccar t cells (1 trial)

cd19 car-t cells (1 trial)

cd19/cd20 bispecific car-t cells (1 trial)

cd33 car-t cells (1 trial)

cd4 car-t cell (3 trials)

cd5 car-t cells (1 trial)

cd7 car-t cell (2 trials)

cll1-cd33 ccar t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 1)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, T-Cell (Phase 1)

Lymphoma (Phase 1)

Lymphoma, T-Cell (Phase 1)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 14
# of Trial APIs: 10